1. Home
  2. BXMX vs FTRE Comparison

BXMX vs FTRE Comparison

Compare BXMX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

BXMX

Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

HOLD

Current Price

$13.70

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$9.87

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXMX
FTRE
Founded
2004
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BXMX
FTRE
Price
$13.70
$9.87
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$15.39
AVG Volume (30 Days)
124.9K
1.6M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
7.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$11.25
$3.97
52 Week High
$15.00
$18.67

Technical Indicators

Market Signals
Indicator
BXMX
FTRE
Relative Strength Index (RSI) 35.06 41.99
Support Level $13.32 $9.05
Resistance Level $14.02 $11.22
Average True Range (ATR) 0.21 0.64
MACD -0.08 0.22
Stochastic Oscillator 13.40 55.28

Price Performance

Historical Comparison
BXMX
FTRE

About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: